ARTV Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $29,999,976.00

Insider Selling (Last 12 Months): $0.00

Artiva Biotherapeutics Insider Trading History Chart

Artiva Biotherapeutics Share Price & Price History

^$5.60

▼ -0.65 (-10.40%)

As of 03/13/2025 05:00 PM ET

Days: 30 | 90 | 365

Artiva Biotherapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/22/2024	Global Strategic Fund I Venbio	Major Shareholder	Buy	416,666	$12.00	$4,999,992.00	1,936,637
7/22/2024	Yong-Jun Huh	Director	Buy	2,083,332	$12.00	$24,999,984.00	3,306,900

SEC Filings (Institutional Ownership Changes) for Artiva Biotherapeutics (NASDAQ:ARTV)

Institutional Buying and Selling by Quarter

Artiva Biotherapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Deutsche Bank AG	21,423	$0.22M	0.0%	N/A	0.088%
2/17/2025	Bank of America Corp DE	10,817	$0.11M	0.0%	-39.3%	0.045%
2/17/2025	BNP Paribas Financial Markets	9,879	$100K	0.0%	+262.1%	0.041%
2/14/2025	Northern Trust Corp	117,112	$1.18M	0.0%	+3.8%	0.482%
2/13/2025	Barclays PLC	24,161	$0.24M	0.0%	+23.2%	0.099%
2/13/2025	Wells Fargo & Company MN	8,616	$87K	0.0%	+64.0%	0.035%
2/12/2025	Geode Capital Management LLC	315,758	$3.18M	0.0%	+2.2%	1.300%
2/12/2025	Norges Bank	30,000	$0.30M	0.0%	N/A	0.124%
2/12/2025	JPMorgan Chase & Co.	37,619	$0.38M	0.0%	+250.7%	0.155%
2/6/2025	Charles Schwab Investment Management Inc.	43,526	$0.44M	0.0%	+8.0%	0.179%
1/30/2025	Rhumbline Advisers	12,879	$0.13M	0.0%	-13.1%	0.053%
1/24/2025	China Universal Asset Management Co. Ltd.	5,150	$52K	0.0%	N/A	0.021%
12/26/2024	JPMorgan Chase & Co.	10,726	$0.17M	0.0%	N/A	0.044%
11/27/2024	Franklin Resources Inc.	520,301	$7.44M	0.0%	N/A	2.142%
11/19/2024	Barclays PLC	19,616	$0.30M	0.0%	N/A	0.081%
11/16/2024	Geode Capital Management LLC	308,930	$4.77M	0.0%	N/A	1.272%
11/15/2024	Barclays PLC	19,616	$0.30M	0.0%	N/A	0.081%
11/15/2024	Wellington Management Group LLP	194,108	$2.91M	0.0%	N/A	0.799%
11/15/2024	State Street Corp	86,559	$1.34M	0.0%	N/A	0.356%
11/15/2024	Samsara BioCapital LLC	291,666	$4.51M	0.9%	N/A	1.201%
11/15/2024	RA Capital Management L.P.	9,853,302	$152.23M	1.8%	N/A	40.565%
11/15/2024	RTW Investments LP	148,844	$2.30M	0.0%	N/A	0.613%
11/14/2024	Acuta Capital Partners LLC	44,000	$0.68M	0.6%	N/A	0.181%
11/14/2024	MetLife Investment Management LLC	8,733	$0.14M	0.0%	N/A	0.036%
11/13/2024	BNP Paribas Financial Markets	2,728	$42K	0.0%	N/A	0.011%
11/12/2024	Charles Schwab Investment Management Inc.	40,293	$0.62M	0.0%	N/A	0.166%

Data available starting January 2016

See Full Table

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Today's Range

Now: $5.60

$5.54

$6.33

50 Day Range

MA: $5.70

$3.68

$10.67

52 Week Range

Now: $5.60

$3.37

$17.31

Volume

99,329 shs

Average Volume

109,004 shs

Market Capitalization

$136.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Artiva Biotherapeutics?: Artiva Biotherapeutics' top insider investors include:
Yong-Jun Huh (Director)
Global Strategic Fund I Venbio (Major Shareholder)
Learn More about top insider investors at Artiva Biotherapeutics.
Who are the major institutional investors of Artiva Biotherapeutics?: Artiva Biotherapeutics' top institutional investors include:
Geode Capital Management LLC — 1.30%
Northern Trust Corp — 0.48%
Charles Schwab Investment Management Inc. — 0.18%
JPMorgan Chase & Co. — 0.15%
Norges Bank — 0.12%
Barclays PLC — 0.10%
Learn More about top institutional investors of Artiva Biotherapeutics stock.
Which major investors are selling Artiva Biotherapeutics stock?: In the previous quarter, ARTV stock was sold by these institutional investors:
Bank of America Corp DE
Rhumbline Advisers
Which major investors are buying Artiva Biotherapeutics stock?: Within the last quarter, ARTV stock was acquired by institutional investors including:
Norges Bank
JPMorgan Chase & Co.
Deutsche Bank AG
BNP Paribas Financial Markets
Geode Capital Management LLC
China Universal Asset Management Co. Ltd.
Barclays PLC
Northern Trust Corp
In the previous year, these company insiders have bought Artiva Biotherapeutics stock:
Yong-Jun Huh (Director)
Global Strategic Fund I Venbio (Major Shareholder)
Learn More investors buying Artiva Biotherapeutics stock.